Objective To isolate and identify Candida auris (C. auris) colonized in the environment of intensive care unit (ICU) and patients' body surface, and analyze the antimicrobial susceptibility. Methods Ninety-six environmental specimens from ICU and 14 specimens from body surfaces of ICU patients with C. auris infection were taken and cultured. Culture products were identified by mass spectrometry and Vitek 2 Compact automated microbial identification system. Species were confirmed by whole genome sequencing (WGS) technology. Antimicrobial susceptibility was determined through minimum inhibitory concentration (MIC). Results 16 strains of C. auris were identified by mass spectrometry, 8 of which were environmental strains and 8 were colonized on the patients' body surface. Vitek 2 Compact system only identified 5 strains. Sixteen environmental/colonized isolates were confirmed to be C. auris through sequencing, exhibiting high genomic similarity with the South Asian branch (Ⅰ) of C. auris. Antimicrobial susceptibility testing results of the 16 C. auris strains were consistent, all of which were resistant to amphotericin and fluconazole, susceptible to 5-fluorocytosine and voriconazole, and susceptible to or intermediated to itraconazole. Conclusion Patients infected with C. auris can cause environmental contamination and colonization on body surface of other patients. Establishing effective monitoring methods for environmental/colonized C. auris can promote infection control.